Codexis (CDXS) Stock: Buy, Sell, or Hold?
CDXS - Codexis, Inc.
$1.47
0.03 (1.74%)
â˛
5d:
+3.17%
30d:
-8.44%
90d:
-39.21%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When CDXS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: CDXS is fairly priced but lacks strong directional signals. At 0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: CDXS is fairly priced but lacks strong directional signals. At 0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: CDXS is currently trading at $1.47, which is considered slightly low relative to its 30-day fair value range of $1.45 to $1.63. From a valuation perspective, the stock is trading at a discount (Forward PE: -4.6) compared to its historical average (16.6). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CDXS is in a strong downtrend. Immediate support is located at $1.41, while resistance sits at $1.72.
Market Sentiment: The stock scores a mixed 50/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $6.33 (+332.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CDXS is in a strong downtrend. Immediate support is located at $1.41, while resistance sits at $1.72.
Market Sentiment: The stock scores a mixed 50/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $6.33 (+332.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$1.45 -
$1.63
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
84.3%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (50/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 332.3% below Wall St target ($6.33)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 53/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.45 -
$1.63
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$1.41
Resistance Level
$1.72
Current Trend
Strong Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.58
Wall Street Target
$6.33
(+332.3%)
Revenue Growth (YoY)
-2.7%
Profit Margin
-39.6%
PE vs Historical
-4.6 vs 16.6
CHEAP
Share & Embed Analysis
Last updated: September 12, 2026 7:50 AM ET
Data refreshes hourly during market hours. Next update: 8:50 AM
Data refreshes hourly during market hours. Next update: 8:50 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CDXS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$88 | 50 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$55 | 49 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
RCKT
Rocket Pharmaceuticals IâĻ |
STRONG BUY
18 analysts |
$9 | 41 HOLD |
|
LRMR
Larimar Therapeutics Inc |
STRONG BUY
11 analysts |
$14 | 58 HOLD |
